Education
About Us
Working with TipRanks
Follow Us
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (HK:2252)
:2252
2252 Stock Chart & Stats
HK$24.44
-HK$0.03(-0.33%)
At close: 4:00 PM EST
HK$24.44
-HK$0.03(-0.33%)
Day’s Range― - ―
52-Week RangeHK$13.50 - HK$33.70
Previous CloseN/A
Volume4.35M
Average Volume (3M)5.91M
Market Cap
HK$29.60B
Enterprise ValueHK$25.84B
Total Cash (Recent Filing)HK$815.79M
Total Debt (Recent Filing)HK$668.22M
Price to Earnings (P/E)―
Beta2.13
Next Earnings
Apr 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding1,024,730,800
10 Day Avg. Volume5,228,361
30 Day Avg. Volume5,906,894
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)31.04
Price to Sales (P/S)33.57
P/FCF Ratio-25.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Rapid Revenue GrowthSustained triple-digit revenue expansion signals strong adoption of MedBot's robotic systems and instruments, providing a larger recurring revenue base. Over the medium term this top-line momentum can fund scale efficiencies, R&D and commercialization if margins improve.
Recurring And Diversified Revenue StreamsA business model combining upfront capital sales with consumables, service contracts and training partnerships creates predictable lifecycle revenue and customer lock-in. This mix supports margin sustainability and long‑term cash conversion as installed base grows.
Strategic Position In Surgical Robotics Amid Secular DemandOperating in a growing, structural market for minimally invasive and robotic surgery gives durable addressable-market expansion. As a focused robotics player, MedBot benefits from secular adoption, clinical partnerships and potential network effects from training and installations.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow constrains internal funding for production scale, service rollout and R&D. Over months this forces reliance on external financing, increasing dilution or interest burden and limiting the firm’s financial flexibility to execute growth plans.
Ongoing Net Losses And Weak MarginsContinued net losses and negative operating margins indicate structural cost or pricing gaps. Without sustained margin improvement, the company may struggle to convert revenue growth into sustainable profits, limiting reinvestment capacity and shareholder returns over the medium term.
Moderately High Leverage And Declining Equity RatioElevated leverage and a falling equity ratio reduce balance-sheet resilience, increasing vulnerability to revenue shocks. With negative ROE, debt amplifies financial risk and could restrict access to affordable capital, pressuring liquidity and strategic initiatives over the coming months.
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H News
2252 FAQ
What was Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price range in the past 12 months?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H lowest stock price was HK$13.50 and its highest was HK$33.70 in the past 12 months.
What is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s market cap?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s market cap is HK$29.60B.
When is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s upcoming earnings report date?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s upcoming earnings report date is Apr 01, 2026 which is in 41 days.
How were Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s earnings last quarter?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H released its earnings results on Aug 28, 2025. The company reported -HK$0.121 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.121.
Is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price is currently Overvalued.
Does Shanghai MicroPort MedBot (Group) Co., Ltd. Class H pay dividends?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H does not currently pay dividends.
What is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s EPS estimate?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai MicroPort MedBot (Group) Co., Ltd. Class H have?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H has 1,024,730,800 shares outstanding.
What happened to Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price movement after its last earnings report?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H reported an EPS of -HK$0.121 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.068%.
Which hedge fund is a major shareholder of Shanghai MicroPort MedBot (Group) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2252
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
200.00%
12-Months-Change
Fundamentals
Return on Equity
-117.51%
Trailing 12-Months
Asset Growth
36.18%
Trailing 12-Months
Company Description
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
Shanghai Microport Medbot (Group) Co., Ltd. engages in the research and development, design, manufacture, and sale of surgical robots in the People's Republic of China and Europe. It offers Toumai, a laparoscopic surgical robot for use in urologic, gynecologic, thoracic, and general surgeries; DFVision, a 3D electronic laparoscope, which is used in laparoscopic surgeries for abdominal, thoracic, and pelvic organs; Honghu, an orthopedic surgical robot for knee arthroplasty and hip arthroplasty; R-One, a vascular interventional surgical robot for coronary angioplasty; and iSR'obot, a Mona Lisa robotic transperineal prostate biopsy system. The company also provides spine surgical robots; trans-bronchial surgical robots for trans-bronchial diagnosis and treatment; TAVR surgical robots for heart valve replacement surgery; and automated needle targeting robotics systems for percutaneous lung biopsy and percutaneous nephrolithotomy. Shanghai Microport Medbot (Group) Co., Ltd. was founded in 2014 and is based in Shanghai, China. Shanghai Microport Medbot (Group) Co., Ltd. operates as a subsidiary of MicroPort Scientific Corporation.
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252) Earnings & Revenues
Technical Analysis
MicroPort Scientific
―
LifeTech Scientific Corporation
―
AK Medical Holdings Ltd.
―
MicroPort CardioFlow Medtech Corp.
―
MicroPort NeuroTech Limited
―
Options Prices
Currently, No data available
---